About Authors:
A.Tamil Selvan*, R.Suresh1, D.Benito Johnson2, R.Suresh Kumar3, R.Venkatanarayanan4, L.Sivakumar5
Department of Pharmacology
Teegala Ram Reddy College of Pharmacy, Meerpet, Hyderabad – 97
1-4RVS College of Pharmaceutical Sciences, Sulur, Coimbatore- 641402
5SKM Siddha and Ayurvedha Company (India) Limited, Erode - 638104.
*tamilselvanpharmacologist@gmail.com
ABSTRACT
In this study, polyherbal extract of Cycas circinalis, Nardostachys jatamansi and Artemisia absinthium ethanolic fraction was explored for its antidepressant property using Forced swim test (FST) and Tail suspension test (TST). Many of its individual constituents have been used for central nervous system (CNS) activities but no systematic work was carried on this combination. In this study its effect on depression was explored in rats. For this purpose the plants part were extracted by successive solvent extraction by Soxhylation. Ethanolic extract was chosen for the pharmacological evaluation, based upon the phytochemical and instrumental analysis. The ethanolic extract was subjected to FT-IR analysis for finding the possible number and nature of function groups present in it. Also the extract was analysed by HPLC for the number possible phytocompounds/phytoconstituents present, which may directly or indirectly involve in the brain neurochemical activity. Acute and Subacute toxicity study revealed the dose upto 2000mg/kg the extract had not toxic symptoms and no mortality. The therapeutic dose was found to be 200mg/kg and there was no toxic damage to liver and kidney observed in subacute toxicity study. The ethanolic extract of the polyherbal combination exhibited significant (P<0.001) antidepressant activity as indicated by its ability to decrease swim stress and tail suspension induced immobility time in rats as compared with that standard Fluoxetine. As well as restoring biogenic amines to normal level that was altered by the swim stress and tail suspension test in whole rat brain assay by HPTLC method. The result indicates this polyherbal combination can be a potential candidate for .managing depression. However further studies are required to confirm the exact therapeutic efficacy.